Host–microbiota interaction during cancer progression from bulk to single-cell level

Abstract

Background: Cancer, a global threat to human health, refers to a large crowd of lethal diseases that can start in almost all tissues or organs of our body when abnormal cells grow uncontrollably and beyond their usual boundaries, followed by invading adjacent normal tissues and spreading to distant organs. Recently, substantial evidence has demonstrated polymorphic microbiome as an emerging cancer characteristic present in a variety of tumour types. By releasing metabolites or other signalling molecules, microbiota can affect immune cell differentiation and activity, including both innate and adaptive immunological responses, as well as the growth and multiplication of cancer cells. It was now employed as a biomarker to predict the patients' survival rate and the degree of cancer progression.

Main: To investigate the underlying mechanism and the technology development of how polymorphic microbiome influence the tumour microenvironment and subsequently cancer progression, we have carried out systematic literature review about polymorphic microbiome and tumour development from bulk to single-cell level.

Conclusions: Here, we provide an overview of the current advancements of host–microbiota interactions during cancer progression from bulk to single-cell level and discuss the challenges and opportunities in future, looking forward to ascertain the specific activity of different somatic cell types with or without the existence of various multi-kingdom microbiota and their by-products and supply a holistic and elaborate investigation of host-microbiota interaction in the development of cancer.

Keywords

cancer / host-microbiota interaction / polymorphic microbiome / single-cell analysis

References

[1] VallianouNG, Stratigou T, TsagarakisS. Metformin and gut microbiota: their interactions and their impact on diabetes. Horm-Int J Endocrino. 2019;18:141-144.

[2] HanahanD. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31-46.

[3] Galeano NinoJL, WuH, LaCourseKD, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022;611:810-817.

[4] YangL, LiA, WangY, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther. 2023;8:35.

[5] LiuNN, JiaoN, TanJC, et al. Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. Nat Microbiol. 2022;7:238-250.

[6] QuigleyEMM. Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci. 2017;17:94.

[7] BinnewiesM, Roberts EW, KerstenK, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541-550.

[8] Sepich-PooreGD, Zitvogel L, StraussmanR, HastyJ, WargoJA, KnightR. The microbiome and human cancer. Science. 2021;371:eabc4552.

[9] ShiY, LiuXF, ZhuangY, et al. Helicobacter pylori-induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice. Journal of Immunology. 2010;184:5121-5129.

[10] Mejias-LuqueR, Zöller J, AnderlF, et al. Lymphotoxin beta receptor signalling executes Helicobacter pylori-driven gastric inflammation in a T4SS-dependent manner. Gut. 2017;66:1369-1381.

[11] PengR, LiuS, YouW, et al. Gastric microbiome alterations are associated with decreased CD8+ tissue-resident memory T cells in the tumor microenvironment of gastric cancer. Cancer Immunol Res. 2022;10:1224-1240.

[12] VitielloGA, CohenDJ, MillerG. Harnessing the microbiome for pancreatic cancer immunotherapy. Trends Cancer. 2019;5:670-676.

[13] WeiMY, ShiS, LiangC, et al. The microbiota and microbiome in pancreatic cancer: more influential than expected. Mol Cancer. 2019;18:97.

[14] ZhangCY, HuA, LiJ, et al. Combined non-invasive prediction and new biomarkers of oral and fecal microbiota in patients with gastric and colorectal cancer. Front Cell Infect Mi. 2022;12:830684.

[15] ZengJ, ZhangG, ChenC, et al. Alterations in urobiome in patients with bladder cancer and implications for clinical outcome: a single-institution study. Front Cell Infect Microbiol. 2020;10:555508.

[16] ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115-132.

[17] PilaniyaV, GeraK, KunalS, Shah A. Pulmonary tuberculosis masquerading as metastatic lung disease. Eur Respir Rev. 2016;25(139):97-98.

[18] MaoQX, JiangF, YinR, et al. Interplay between the lung microbiome and lung cancer. Cancer Lett. 2018;415:40-48.

[19] LiuNN, JiaoN, TanJC, et al. Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. Nature Microbiology. 2022;7:238-250.

[20] LiuNN, YiCX, WeiLQ, et al. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell. 2023;41(11):1927-1944.

[21] LiuNN, MaQ, GeY, et al. Microbiome dysbiosis in lung cancer: from composition to therapy. NPJ Precis Oncol. 2020;4:33.

[22] MauceriR, Coppini M, VaccaD, et al. No clear clustering dysbiosis from salivary microbiota analysis by long sequencing reads in patients affected by oral squamous cell carcinoma: a single center study. Cancers. 2023;15:4211.

[23] WangXL, XuHW, LiuNN. Oral microbiota: a new insight into cancer progression, diagnosis and treatment. Phenomics. 2023;3:535-547.

[24] MartiniG, Ciardiello D, DallioM, et al. Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab. Int J Cancer. 2022;151:473-480.

[25] ZhangSL, ChengLS, ZhangZY, Sun HT, LiJJ. Untangling determinants of gut microbiota and tumor immunologic status through a multi-omics approach in colorectal cancer. Pharmacol Res. 2023;188:106633.

[26] ChenL, LiZ, ZengT, et al. Identifying robust microbiota signatures and interpretable rules to distinguish cancer subtypes. Front Mol Biosci. 2020;7:604794.

[27] ChaiXQ, WangJ, LiH, et al. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma. Gut Microbes. 2023;15:2156255.

[28] BullmanS. The intratumoral microbiota: from microniches to single cells. Cell. 2023;186:1532-1534.

[29] YangWL, ZhaoY, GeQ, et al. Genetic mutation and tumor microbiota determine heterogenicity of tumor immune signature: evidence from gastric and colorectal synchronous cancers. Front Immunol. 2022;13:947080.

[30] LamKC, ArayaRE, HuangA, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021;184:5338-5356.

[31] IbrahimA, Hugerth LW, HasesL, et al. Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. Int J Cancer. 2019;144:3086-3098.

[32] CampbellC, DikiyS, BhattaraiSK, et al. Extrathymically generated regulatory T cells establish a niche for intestinal border-dwelling bacteria and affect physiologic metabolite balance. Immunity. 2018;48:1245-1257.

[33] PorrasAM, ShiQ, ZhouH, et al. Geographic differences in gut microbiota composition impact susceptibility to enteric infection. Cell Reports. 2021;36:109457.

[34] BelkaidY, Harrison OJ. Homeostatic immunity and the microbiota. Immunity. 2017;46:562-576.

[35] WojnoEDT, ArtisD. Emerging concepts and future challenges in innate lymphoid cell biology. J Exp Med. 2016;213(11):2229-2248.

[36] JinC, Lagoudas GK, ZhaoC, et al. Commensal microbiota promote lung cancer development via gammadelta T cells. Cell. 2019;176:998-1013. e1016

[37] IidaN, Dzutsev A, StewartCA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967-970.

[38] RiquelmeE, ZhangY, ZhangL, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019;178:795-806. e712.

[39] SivanA, Corrales L, HubertN, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084-1089.

[40] PushalkarS, Hundeyin M, DaleyD, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8:403-416.

[41] WuJX, Abraham SN. The roles of T cells in bladder pathologies. Trends Immunol. 2021;42:248-260.

[42] Montalban-ArquesA, Katkeviciute E, BusenhartP, et al. Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe. 2021;29:1573-1588.

[43] ChenHY, TongT, LuSY, et al. Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis. Cell Metab. 2023;35:651-666.

[44] Pleguezuelos-ManzanoC, Puschhof J, Rosendahl HuberA, et al. Mutational signature in colorectal cancer caused by genotoxic pks⁺E. coli. Nature. 2020;580:269-273.

[45] UrbaniakC, GloorGB, BrackstoneM, Scott L, TangneyM, ReidG. The microbiota of breast tissue and its association with breast cancer. Appl Environ Microb. 2016;82:5039-5048.

[46] FuA, YaoB, DongT, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell. 2022;185:1356-1372.

[47] NejmanD, Livyatan I, FuksG, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368:973-980.

[48] Narunsky-HazizaL, Sepich-Poore GD, LivyatanI, et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell. 2022;185:3789-3806.

[49] DohlmanAB, KlugJ, MeskoM, et al. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell. 2022;185:3807-3822.

[50] HouK, WuZX, ChenXY, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7:135.

[51] Rozenblatt-RosenO, Regev A, OberdoerfferP, et al. The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution. Cell. 2020;181:236-249.

[52] Llorens-RicoV, Simcock JA, HuysGRB, RaesJ. Single-cell approaches in human microbiome research. Cell. 2022;185:2725-2738.

[53] LanF, Demaree B, AhmedN, AbateAR. Single-cell genome sequencing at ultra-high-throughput with microfluidic droplet barcoding. Nature Biotechnology. 2017;35:640-646.

[54] ZhengW, ZhaoS, YinY, et al. High-throughput, single-microbe genomics with strain resolution, applied to a human gut microbiome. Science. 2022;376:eabm1483.

[55] LiX, XuL, DemareeB, et al. Microbiome single cell atlases generated with a commercial instrument. bioRxiv. Published online August 10, 2023.

[56] GhaddarB, BiswasA, HarrisC, et al. Tumor microbiome links cellular programs and immunity in pancreatic cancer. Cancer Cell. 2022;40:1240-1253.

[57] YooJY, GroerM, DutraSVO, Sarkar A, McSkimmingDI. Gut microbiota and immune system interactions. Microorganisms. 2020;8:1587.

[58] PanebiancoC, Villani A, PisatiF, et al. Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models. Biomed Pharmacother. 2022;151:113163.

[59] KangX, LiuC, DingY, et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. Gut. 2023;72:2112-2122.

[60] BrancoliniC, Gagliano T, MinisiniM. HDACs and the epigenetic plasticity of cancer cells: target the complexity. Pharmacol Ther. 2022;238:108190.

[61] EslamiM, Sadrifar S, KarbalaeiM, KeikhaM, Kobyliak NM, YousefiB. Importance of the microbiota inhibitory mechanism on the Warburg effect in colorectal cancer cells. J Gastrointest Cancer. 2020;51:738-747.

[62] LiQ, DingC, MengT, et al. Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner. J Pharmacol Sci. 2017;135:148-155.

[63] TaoR, de Zoeten EF, OzkaynakE, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13:1299-1307.

[64] DahiyaS, BeierUH, WangL, et al. HDAC10 deletion promotes Foxp3(+) T-regulatory cell function. Sci Rep. 2020;10:424.

[65] YangW, YuT, HuangX, et al. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun. 2020;11:4457.

[66] ChenL, SunM, WuW, et al. Microbiota Metabolite butyrate differentially regulates Th1 and Th17 cells' differentiation and function in induction of colitis. Inflamm Bowel Dis. 2019;25:1450-1461.

[67] ArpaiaN, Campbell C, FanX, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451-455.

[68] SchulthessJ, PandeyS, CapitaniM, et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity. 2019;50:432-445.

[69] YangX, ZhangZ, ShenX, et al. Clostridium butyricum and its metabolite butyrate promote ferroptosis susceptibility in pancreatic ductal adenocarcinoma. Cell Oncol (Dordr). 2023;46(6):1645-1658.

[70] Correa-OliveiraR, Fachi JL, VieiraA, SatoFT, VinoloMA. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunology. 2016;5:e73.

[71] RezenT, RozmanD, KovácsT, et al. The role of bile acids in carcinogenesis. Cell Mol Life Sci. 2022;79:243.

[72] JangJY, ImE, ChoiYH, Kim ND. Mechanism of bile acid-induced programmed cell death and drug discovery against cancer: a review. Int J Mol Sci. 2022;23:7184.

[73] XieG, WangX, HuangF, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer. 2016;139:1764-1775.

[74] SongX, SunX, OhSF, et al. Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis. Nature. 2020;577:410-415.

[75] CampbellC, McKenney PT, KonstantinovskyD, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature. 2020;581:475-479.

[76] HangS, PaikD, YaoL, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature. 2019;576:143-148.

[77] BachmannAS, GeertsD. Polyamine synthesis as a target of MYC oncogenes. J Biol Chem. 2018;293:18757-18769.

[78] IgnatenkoNA, BabbarN, MehtaD, Casero RA, GernerEW. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog. 2004;39:91-102.

[79] CaseroRA, Stewart TM, PeggAE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer. 2018;18:681-695.

[80] MatsumotoM, Kurihara S, KibeR, AshidaH, BennoY. Longevity in mice is promoted by probiotic-induced suppression of colonic senescence dependent on upregulation of gut bacterial polyamine production. Plos One. 2011;6:e23652.

[81] YoshimotoS, Mitsuyama E, YoshidaK, OdamakiT, XiaoJZ. Enriched metabolites that potentially promote age-associated diseases in subjects with an elderly-type gut microbiota. Gut Microbes. 2021;13:1-11.

[82] HolbertCE, CullenMT, CaseroRA, Stewart TM. Polyamines in cancer: integrating organismal metabolism and antitumour immunity. Nat Rev Cancer. 2022;22:467-480.

[83] ManniA, Washington S, HuX, et al. Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells. Clin Exp Metastasis. 2005;22:255-263.

[84] RooksMG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16:341-352.

[85] LeY, MurphyPM, WangJM. Formyl-peptide receptors revisited. Trends Immunol. 2002;23:541-548.

[86] AykutB, Pushalkar S, ChenR, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 2019;574:264-267.

[87] WangQ, LiuZ, MaA, LiZ, LiuB, MaQ. Computational methods and challenges in analyzing intratumoral microbiome data. Trends Microbiol. 2023;31:707-722.

[88] GaoR, GaoZ, HuangL, Qin H. Gut microbiota and colorectal cancer. Eur J Clin Microbiol Infect Dis. 2017;36:757-769.

[89] ArabJP, Martin-Mateos RM, ShahVH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int. 2018;12:S24-S33.

[90] SalemI, RamserA, IshamN, Ghannoum MA. The Gut microbiome as a major regulator of the gut-skin axis. Front Microbiol. 2018;9:1459.

[91] ColbertLE, El Alam MB, WangR, et al. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023;41:1945-1962.

[92] BelheouaneM, GuptaY, KunzelS, Ibrahim S, BainesJF. Improved detection of gene-microbe interactions in the mouse skin microbiota using high-resolution QTL mapping of 16S rRNA transcripts. Microbiome. 2017;5:59.

[93] SchmiesterM, MaierR, RiedelR, et al. Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma. Gut Microbes. 2022;14:2081475.

[94] McKeeAM, KirkupBM, MadgwickM, et al. Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. Iscience. 2021;24:103012.

[95] WangM, Rousseau B, QiuK, et al. Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses. Nat Biotechnol. Published online September 23, 2023.

[96] PanBL, ChenZ, ZhangX, et al. 2,5-Dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis. J Immunother Cancer. 2023;11:e006817.

[97] KalaoraS, NaglerA, NejmanD, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021;592:138.

[98] PooreGD, Kopylova E, ZhuQ, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579:567.

[99] LamontRJ, Fitzsimonds ZR, WangH, GaoS. Role of Porphyromonas gingivalis in oral and orodigestive squamous cell carcinoma. Periodontol 2000. 2022;89:154-165.

[100] MaJ, Gnanasekar A, LeeA, et al. Influence of intratumor microbiome on clinical outcome and immune processes in prostate cancer. Cancers (Basel). 2020;12:2524.

[101] YamamuraK, BabaY, NakagawaS, et al. Human microbiome in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22:5574-5581.

[102] ApostolouP, et al. Bacterial and fungal microflora in surgically removed lung cancer samples. J Cardiothorac Surg. 2011;6:137.

[103] BadgerJL, StinsMF, KimKS. Citrobacter freundii invades and replicates in human brain microvascular endothelial cells. Infect Immun. 1999;67:4208-4215.

[104] FanX, Alekseyenko AV, WuJ, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018;67:120-127.

[105] PanG, WangX, WangY, et al. Helicobacter pylori promotes gastric cancer progression by upregulating semaphorin 5A expression via ERK/MMP9 signaling. Mol Ther Oncolytics. 2021;22:256-264.

[106] BullmanS, Pedamallu CS, SicinskaE, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358:1443-1448.

[107] WangX, JiaY, WenL, et al. Porphyromonas gingivalis promotes colorectal carcinoma by activating the hematopoietic NLRP3 inflammasome. Cancer Res. 2021;81:2745-2759.

[108] DejeaCM, FathiP, CraigJM, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 2018;359:592-597.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.